MIR. MedMira Inc.

MedMira Announces AGM Results

MedMira Announces AGM Results

HALIFAX, Nova Scotia, June 03, 2019 (GLOBE NEWSWIRE) -- MedMira Inc. (MedMira) (TSXV: MIR) held its 2019 Annual General Meeting of Shareholders on May 31, 2019 in Halifax, Nova Scotia.  Incumbent Director Mr. Hermes Chan was re-elected and Mr. Jianhe Mao and Mr. Steven Cummings were elected to the Board during the meeting.  Dr. Shou-Ching Tang and Ms. Lili Zhao chose not to stand for re-election to the MedMira Board of Directors.   

Mr. Jianhe Mao is the owner of Unipec, a consulting firm based in St. Gallen, Switzerland, focusing on assisting European companies enter the Chinese market, through operational restructuring and ownership and management optimization.  Mr. Mao is also involved in several industrial projects and start-up ventures and serves on the boards of several European companies.  He is regarded as a trusted expert in legal cases, corporate corruption, operational turnarounds, and mergers and acquisitions.  Mr. Mao began his career as a project engineer and has gained experience in business development and real estate investment.  He holds an M.E. from Ruhr University Bochum.

Mr. Steven Cummings is the Founder & President of Cambridge Financial Services, one of the leading full service accounting, tax, and business advisory firms in Nova Scotia.  Under Mr. Cummings leadership, Cambridge Financial has earned an enviable reputation among businesses and industry for a commitment to high standards. Along with his leadership responsibilities at Cambridge Financial Services, Mr. Cummings was engaged as MedMira’s interim Chief Financial Officer in 2007.  With more than 30 years of financial and entrepreneurial experience, Mr. Cummings is a frequent guest speaker on issues surrounding provincial taxation, taxation of seniors, and business ownership.

“Our new directors, Mr. Mao and Mr. Cummings, bring their specific areas of business and financial expertise to MedMira and the management team looks forward to welcoming and working with our new board members as we move the Company forward,” said Hermes Chan, Director and President & CEO, MedMira Inc.  “The Company thanks Dr. Tang and Ms. Zhao for their service as directors.”

Shareholders also approved the appointment of ArsenaultBestCameronEllis as the Company’s auditors during the meeting.

About MedMira

MedMira is the developer and owner of Rapid Vertical Flow (RVF) Technologyä. The Company’s rapid test applications built on RVF Technology provide hospitals, labs, clinics and individuals with instant diagnosis for diseases such as HIV and hepatitis C in just three easy steps. The Company’s tests are sold under the Reveal, Multiplo and Miriad brands in global markets. MedMira’s corporate offices and manufacturing facilities are located in Halifax, Nova Scotia, Canada and the Company has a sales and customer service office located the United States. For more information visit . Follow us on and .

This news release contains forward-looking statements, which involve risk and uncertainties and reflect the Company’s current expectation regarding future events including statements regarding possible approval and launch of new products, future growth, and new business opportunities.  Actual events could materially differ from those projected herein and depend on a number of factors including, but not limited to, changing market conditions, successful and timely completion of clinical studies, uncertainties related to the regulatory approval process, establishment of corporate alliances and other risks detailed from time to time in the company quarterly filings.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

MedMira Contacts:

Markus Meile, CFO                                              

Tel: 902-450-1588                                              

Email:                          

Andrea Young, Corporate Communications

Tel: 902-450-1588

Email:

EN
03/06/2019

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on MedMira Inc.

 PRESS RELEASE

EQS-News: MedMira provides Progress Update

EQS-News: MedMira Inc. MedMira provides Progress Update 03.10.2022 / 13:04 CET/CEST The issuer is solely responsible for the content of this announcement. Today, MedMira Inc. (MedMira) (TSXV: MIR) announces the appointment of Dr. Sam Ratnam as MedMira’s Director of Scientific & Regulatory Affairs and provides an update on its regulatory progress in the U.S. market.U.S. Regulatory Update on COVID-19 ProductsThe recent announced recommendation by the U.S. FDA to IVD manufacturers to apply for the traditional regulatory path 510(k) approval outlines the continuous need for qua...

 PRESS RELEASE

VYRA™ Product Line Update

VYRA™ Product Line Update HALIFAX, Nova Scotia, May 20, 2022 (GLOBE NEWSWIRE) -- Today, MedMira Inc. (MedMira) (TSXV: MIR) provides an update on the Company’s regulatory work for Canada for its VYRA™ product line. On the 10th of May 2022, Health Canada issued to all stakeholder further information about the current Interim Order No. 3. As a result, the regulators have clearly defined the pathway to achieve the Interim Order and with it provided the Company with the last requirement to complete its final application for their review. The final condition for MedMira is to complete an addit...

 PRESS RELEASE

MedMira receives CE mark for Multiplo® Complete Syphilis (TP/nTP) Anti...

MedMira receives CE mark for Multiplo® Complete Syphilis (TP/nTP) Antibody Test HALIFAX, Nova Scotia, May 12, 2022 (GLOBE NEWSWIRE) -- Today, MedMira Inc. (MedMira) (TSXV: MIR) announces the achievement of another milestone in its regulatory strategy by receiving the CE mark for its Multiplo® Complete Syphilis (TP/nTP) Antibody Test (Multiplo® TP/nTP). This approval allows the Company to further strengthen its product offering in all markets accepting the CE mark. By utilizing its unique RVF technology®, MedMira offers the only commercially available combined screening and confirmation te...

 PRESS RELEASE

MedMira reports additional independent performance evaluation results ...

MedMira reports additional independent performance evaluation results of REVEALCOVID-19™ Total Antibody Test

 PRESS RELEASE

MedMira gibt exklusive Vertriebspartnerschaft mit Webb Diagnostic Tech...

MedMira gibt exklusive Vertriebspartnerschaft mit Webb Diagnostic Technologies für Gesamtantikörpertest REVEALCOVID-19™ in den USA und erste Bestellung bekannt HALIFAX, Nova Scotia, May 28, 2020 (GLOBE NEWSWIRE) -- MedMira Inc. (MedMira) (TSXV: MIR) gibt bekannt, dass das Unternehmen für den Vertrieb des Gesamtantikörpertests REVEALCOVID-19™ eine exklusive Vertriebsvereinbarung mit Webb Diagnostic Technologies, Inc. (WebbDX) abgeschlossen hat.  Webb Diagnostic Technologies hat seine erste Bestellung im Wert von ca. 3,5 Millionen CAD aufgegeben. MedMira hat eine Anzahlung erhalten, um den ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch